SWOG clinical trial number
S9920
A Phase III Randomized Study Comparing Busulfan – Total Body Irradiation Versus Cyclophosphamide – Total Body Irradiation Preparative Regimen in Patients with Advanced Myelodysplastic Syndrome (MDS) or MDS – Related Acute Myeloid Leukemia (AML) Undergoing HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation, (A BMT Study)
Closed
Phase
Accrual
0%
Abbreviated Title
Advanced MDS / MDS-Related AML
Activated
06/15/2000
Closed
10/15/2001
Participants
Limited Institutions: SWOG Approved Autologous BMT Facilities
Research committees
Leukemia
Treatment
Cyclophosphamide
Busulfan
Radiation Therapy
Eligibility Criteria Expand/Collapse
Diagnosis of MDS or MDS-related AML subclassifiable according to the criteria in Sections 4.0 and 5.1 of the protocol; previously untreated for MDS or MDS-related AML; patients must be between the ages of 16-55; Zubrod PS 0-2, must have a genotypically HLA-identical matched sibling (at least 4 major antigen matches) and be HIV negative.
Other Clinical Trials
SWOG Clinical Trial Number
S2504
A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302
Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase
SWOG Clinical Trial Number
S1925
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Management and Survivorship
Activated
12/14/2020
Accrual
83%
Open
Phase